Company Number: 14073885

Analysis Date: 2025-07-20 17:19 UTC

Financial Health Assessment for CHESTPAL LTD (as of 31 March 2024)

---

1. Financial Health Score: C

Explanation:
CHESTPAL LTD shows a mixed financial condition. While the company has strong shareholder equity and significant intangible assets reflecting investment in development, it exhibits concerning signs in liquidity and working capital management. Negative net current assets and a sharp decline in cash reserves are symptoms of financial strain that need attention to avoid distress.

---

2. Key Vital Signs

Vital Sign	2024 Value	2023 Value	Interpretation
Fixed Assets	£503,752	£164,491	Significant increase mainly from intangible assets (development costs and patents), indicating investment in innovation and product development. Healthy for a tech/medical equipment firm.
Current Assets	£75,613	£463,234	Sharp decline, mostly cash, showing liquidity tightening ("weak pulse").
Cash at Bank	£40,905	£386,506	Large depletion in cash reserves — a red flag for short-term survival without additional funding.
Debtors	£10,085	£11,931	Stable but low, no major concerns here.
Current Liabilities	£98,407	£51,053	Nearly doubled, increasing short-term obligations ("higher blood pressure" on liquidity).
Net Current Assets (Working Capital)	(£22,794)	£412,181	Negative working capital signals inability to cover short-term debts with short-term assets—a critical symptom of financial distress.
Total Assets Less Current Liabilities	£480,958	£576,672	Decrease reflects overall net asset contraction but still positive.
Shareholders Funds (Equity)	£1,619,025	£860,553	Strong equity base, boosted by share premium, showing investor confidence and capital injections ("healthy heart").
Retained Earnings	(£1,139,547)	(£285,143)	Large accumulated losses indicating ongoing operating losses, a chronic illness for profitability.

---

3. Diagnosis

• Liquidity Crisis: The company’s cash reserves have been severely depleted from £386k to just £41k within a year, while current liabilities have almost doubled. This negative working capital is akin to a patient showing symptoms of dehydration and shock—urgent intervention is needed to restore fluid (cash) levels.

• Investment in Growth: The surge in intangible assets (patents and development costs) suggests the company is heavily investing in innovation. This is a positive sign for long-term viability but currently burdens the balance sheet with costs before revenue benefits are realised.

• Profitability Struggles: The large negative retained earnings indicate the company is in a loss-making phase, common for startups or R&D-heavy firms but unsustainable without strong funding or revenue growth.

• Strong Capital Backbone: The substantial increase in shareholders’ funds (mainly share premium) shows that the company has successfully raised additional equity capital, providing a financial buffer and “immune system” support.

• Going Concern: Directors confirm the company is a going concern based on projected equity funding and cash flow, indicating confidence but dependent on continued capital injections.

---

4. Recommendations

1. Urgent Cash Flow Management:

   • Tighten control on expenses and delay non-essential spending.
   • Accelerate collection of receivables and negotiate longer payment terms with suppliers.
   • Consider short-term bridging finance to stabilize cash flow.

2. Capital Raising Strategy:

   • Plan for further equity funding rounds or alternative financing (e.g., grants, R&D tax credits, government support) to strengthen liquidity.
   • Communicate clearly with investors about the company’s innovation pipeline and path to profitability.

3. Monitor Working Capital:

   • Avoid negative net current assets by balancing current asset and liability growth.
   • Evaluate inventory management to reduce stock levels and free up cash.

4. Operational Efficiency:

   • Review cost structures especially overheads and production costs.
   • Focus on revenue-generating activities to improve profitability.

5. Financial Reporting Improvements:

   • Consider audited accounts for greater transparency and investor confidence once scale warrants.
   • Implement regular financial health checks and forecasting to anticipate liquidity needs.

---

Medical Analogy Summary:

CHESTPAL LTD’s financial health resembles a patient with a strong heartbeat (equity funding) and good long-term prognosis due to investment in innovation, but currently suffering from dehydration and shock (liquidity crisis and negative working capital). Immediate fluid resuscitation (cash injections and cost control) is essential to stabilize the patient before they can benefit from their growth and development efforts.

---